60 Degrees Pharmaceuticals Inc. Common Stock SXTP · Stock Open 60 Degrees Pharmaceuticals Inc. Common Stock in new tab
60 Degrees Pharmaceuticals Inc. Common Stock Analysis (SXTP)
Is 60 Degrees Pharmaceuticals Inc. Common Stock a good investment? 60 Degrees Pharmaceuticals Inc. Common Stock (SXTP) is currently trading at 1.06 USD.
Earnings Schedule: 60 Degrees Pharmaceuticals Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -3.58.
Investor FAQ
Does 60 Degrees Pharmaceuticals Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is 60 Degrees Pharmaceuticals Inc. Common Stock?
60 Degrees Pharmaceuticals Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -2.67.
Company Profile
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 12, 2024 | 1:12 |
| Feb. 24, 2025 | 1:5 |
| Jan. 20, 2026 | 1:4 |
Community Discussion